A study by Malholtra et al. showed that the IFN-β treatment attenuated the course and severity of MS by reducing the activity of NLRP3 inflammasomes via suppressing caspase-1 dependent IL-1β secretion (112). The gene discussed is IFNB1; the disease is myeloid sarcoma.